Tezspire: FDA Approves New Option for Chronic Sinus Inflammation With Nasal Polyps

Written by Joyani Das, PhD
Medically Reviewed by Francisco Talavera, PhD, PharmD on October 20, 2025
3 min read

Tezspire (tezepelumab-ekko) is a prescription medicine used to treat inflammatory conditions of the airways, such as severe asthma. The FDA has now approved it as an add-on treatment for adults and children aged 12 and older with chronic rhinosinusitis with nasal polyps (CRSwNP) that is not well controlled with current treatments. Tezspire is a lab-made antibody that blocks certain parts of your immune system that cause inflammation.

CRSwNP causes swelling in the sinuses and leads to growths called polyps in the nose. These can block airflow, reduce your sense of smell, and make you feel congested. It’s estimated that up to 320 million people around the world live with this condition.

Tezspire works by blocking a protein called thymic stromal lymphopoietin (TSLP), which plays a key role in causing inflammation in the airways and sinuses. This inflammation can make breathing difficult and worsen symptoms of CRSwNP and asthma. First approved in 2021 as an add-on treatment for severe asthma, Tezspire offers a new option for people living with this chronic condition.

Tezspire was approved to treat CRSwNP after studies showed it helped shrink nasal polyps and ease nasal congestion.

In the study, people received either Tezspire or a placebo every four weeks for a year, along with their usual nasal steroid treatment. Those who got this medicine had more improvement in both polyp size and congestion than those who got the placebo. Benefits appeared as early as week 2 for congestion and week 4 for polyp size and were maintained for a year.

Tezspire also reduced the need for nasal polyp surgery by 98% and cut steroid use by 88%. The safety of this medicine in people with CRSwNP was similar to what was seen in people with asthma.

Common side effects in CRSwNP are cold or flu-like symptoms (such as sore throat, stuffy nose, or cough), nosebleeds, back pain, joint pain, and reactions at the injection site, such as redness or swelling.

Tezspire is given as a shot under the skin once every four weeks. It comes in a single-dose vial, a prefilled syringe, or a prefilled pen. Your health care provider may give you the injection, or they may train you or a caregiver to give it at home using the prefilled pen.

Keep taking your other medicines, including corticosteroids, unless your health care provider advises otherwise. Stopping them may cause your symptoms to return.

You should not use this medicine if you are allergic to tezepelumab-ekko or any of its ingredients. Serious allergic reactions, including anaphylaxis (a life-threatening allergic reaction), have been reported. Your health care provider will watch for these reactions and may take steps to manage them if they occur. Tell your health care provider if you’ve had a serious allergic reaction in the past or have a parasitic infection.

Also, let them know about your medical history and all the medicines, supplements, and over-the-counter products you take to help avoid harmful interactions. Inform about scheduled vaccines as you shouldn’t get live vaccines while on this medicine.

If you’re pregnant or breastfeeding, or plan to become pregnant, talk to your health care provider as it is not known if Tezspire can harm a fetus or pass into breastmilk. 

Talk to your health care provider to see if Tezspire might be right for you, especially if your current treatment isn’t providing enough relief for CRSwNP.